Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.47 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.47 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.44 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.43 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12406649 | 0.85 | PDK1 (0.53) | LMNAPOLBNPC1RAB9APDK1 | |
| SCHEMBL635520 | 0.85 | PDK1 (0.53) | LMNAPOLBNPC1RAB9APDK1 | |
| SCHEMBL734814 | 0.83 | NPC1 (0.49) | LMNAPOLBP2RX1NPC1RAB9A | |
| SCHEMBL734815 | 0.83 | NPC1 (0.49) | LMNAPOLBP2RX1NPC1RAB9A | |
| SCHEMBL2341103 | 0.81 | PPARA (0.38) | LMNAPOLBNPC1RAB9APDK1 | |
| SCHEMBL1634810 | 0.79 | SMN1; SMN2 (0.56) | LMNAPOLBP2RX1RAB9AALDH1A1 | |
| SCHEMBL1634808 | 0.79 | SMN1; SMN2 (0.56) | LMNAPOLBP2RX1RAB9AALDH1A1 | |
| SCHEMBL3042876 | 0.79 | MMP2 (0.50) | POLBNPC1RAB9AALDH1A1GAA | |
| SCHEMBL13224065 | 0.79 | MMP2 (0.50) | POLBNPC1RAB9AALDH1A1GAA | |
| SCHEMBL13240798 | 0.78 | MMP12 (0.48) | LMNAPOLBP2RX1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358736-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | Intermune, Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010045266-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010045266-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | SARS1, VIP, MAVS | LMNA 3507/4885POLB 545/4885P2RX1 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.